ASX:CSLBiotechs
A Look At CSL (ASX:CSL) Valuation After Guidance Cut Impairments CEO Change And Share Price Rebound
CSL (ASX:CSL) is back in focus after cutting its FY26 revenue guidance, flagging about US$5b in additional Vifor related impairments and progressing a CEO transition along with broader commercial restructuring.
See our latest analysis for CSL.
CSL’s share price rose 5.75% in the last session to A$97.91 and is up 1.35% over seven days. However, the 30 day share price return is down 18.33% and the one year total shareholder return is down 58.53%, which points to fading longer term momentum...